Six Flags Entertainment Statistics
Total Valuation
NovoCure has a market cap or net worth of $1.27 billion. The enterprise value is $1.06 billion.
Important Dates
The last earnings date was Thursday, July 24, 2025, before market open.
| Earnings Date | Jul 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 111.80 million shares outstanding. The number of shares has increased by 2.25% in one year.
| Current Share Class | 111.80M |
| Shares Outstanding | 111.80M |
| Shares Change (YoY) | +2.25% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 9.61% |
| Owned by Institutions (%) | 85.39% |
| Float | 101.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.99 |
| Forward PS | 1.92 |
| PB Ratio | 3.66 |
| P/TBV Ratio | 3.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 2.00.
| Current Ratio | 1.45 |
| Quick Ratio | 1.39 |
| Debt / Equity | 2.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.27 |
Financial Efficiency
Return on equity (ROE) is -48.07% and return on invested capital (ROIC) is -10.17%.
| Return on Equity (ROE) | -48.07% |
| Return on Assets (ROA) | -8.64% |
| Return on Invested Capital (ROIC) | -10.17% |
| Return on Capital Employed (ROCE) | -34.22% |
| Revenue Per Employee | $423,495 |
| Profits Per Employee | -$114,886 |
| Employee Count | 1,488 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 3.67 |
Taxes
In the past 12 months, NovoCure has paid $28.89 million in taxes.
| Income Tax | 28.89M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.97% in the last 52 weeks. The beta is 0.61, so NovoCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -44.97% |
| 50-Day Moving Average | 16.25 |
| 200-Day Moving Average | 20.01 |
| Relative Strength Index (RSI) | 27.45 |
| Average Volume (20 Days) | 1,993,434 |
Short Selling Information
The latest short interest is 4.93 million, so 4.41% of the outstanding shares have been sold short.
| Short Interest | 4.93M |
| Short Previous Month | 5.23M |
| Short % of Shares Out | 4.41% |
| Short % of Float | 4.88% |
| Short Ratio (days to cover) | 3.87 |
Income Statement
In the last 12 months, NovoCure had revenue of $630.16 million and -$170.95 million in losses. Loss per share was -$1.56.
| Revenue | 630.16M |
| Gross Profit | 482.34M |
| Operating Income | -169.83M |
| Pretax Income | -141.13M |
| Net Income | -170.95M |
| EBITDA | -158.86M |
| EBIT | -169.83M |
| Loss Per Share | -$1.56 |
Full Income StatementBalance Sheet
The company has $911.53 million in cash and $700.25 million in debt, giving a net cash position of $211.27 million or $1.89 per share.
| Cash & Cash Equivalents | 911.53M |
| Total Debt | 700.25M |
| Net Cash | 211.27M |
| Net Cash Per Share | $1.89 |
| Equity (Book Value) | 349.44M |
| Book Value Per Share | 3.13 |
| Working Capital | 333.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$44.68 million and capital expenditures -$35.72 million, giving a free cash flow of -$80.40 million.
| Operating Cash Flow | -44.68M |
| Capital Expenditures | -35.72M |
| Free Cash Flow | -80.40M |
| FCF Per Share | -$0.72 |
Full Cash Flow StatementMargins
Gross margin is 76.54%, with operating and profit margins of -26.95% and -27.13%.
| Gross Margin | 76.54% |
| Operating Margin | -26.95% |
| Pretax Margin | -22.54% |
| Profit Margin | -27.13% |
| EBITDA Margin | -25.21% |
| EBIT Margin | -26.95% |
| FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.25% |
| Shareholder Yield | -2.25% |
| Earnings Yield | -13.50% |
| FCF Yield | -6.35% |
Dividend DetailsAnalyst Forecast
The average price target for NovoCure is $28.79, which is 152.77% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.79 |
| Price Target Difference | 152.77% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 18.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.44 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.44 |
| Piotroski F-Score | 4 |
